DE10066210B4 - Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques - Google Patents

Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques Download PDF

Info

Publication number
DE10066210B4
DE10066210B4 DE10066210A DE10066210A DE10066210B4 DE 10066210 B4 DE10066210 B4 DE 10066210B4 DE 10066210 A DE10066210 A DE 10066210A DE 10066210 A DE10066210 A DE 10066210A DE 10066210 B4 DE10066210 B4 DE 10066210B4
Authority
DE
Germany
Prior art keywords
mmol
tetraazacyclododecane
dissolved
stirred
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10066210A
Other languages
German (de)
English (en)
Inventor
Ulrich Niedballa
Bernd Misselwitz
Johannes Platzek
Peter Mareski
Hans-Joachim Weinmann
Bernd Radüchel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to DE10040380A priority Critical patent/DE10040380B4/de
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application granted granted Critical
Publication of DE10066210B4 publication Critical patent/DE10066210B4/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE10066210A 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques Expired - Fee Related DE10066210B4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Publications (1)

Publication Number Publication Date
DE10066210B4 true DE10066210B4 (de) 2008-02-28

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10066210A Expired - Fee Related DE10066210B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Country Status (26)

Country Link
EP (1) EP1307236A2 (ko)
JP (1) JP2004506025A (ko)
KR (1) KR20030022387A (ko)
CN (1) CN1469757A (ko)
AR (1) AR034139A1 (ko)
AU (2) AU7754901A (ko)
BG (1) BG107542A (ko)
BR (1) BR0113188A (ko)
CA (1) CA2419223A1 (ko)
CZ (1) CZ2003392A3 (ko)
DE (1) DE10066210B4 (ko)
EE (1) EE200300061A (ko)
HR (1) HRP20030173A2 (ko)
HU (1) HUP0300736A3 (ko)
IL (1) IL154385A0 (ko)
MX (1) MXPA03001287A (ko)
NO (1) NO20030604L (ko)
NZ (1) NZ523932A (ko)
PL (1) PL365596A1 (ko)
RU (1) RU2290206C2 (ko)
SK (1) SK1572003A3 (ko)
TW (1) TWI296931B (ko)
UA (1) UA82642C2 (ko)
WO (1) WO2002013874A2 (ko)
YU (1) YU10603A (ko)
ZA (1) ZA200301949B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11104639B2 (en) 2016-09-14 2021-08-31 Daikin Industries, Ltd. Branched fluorine-containing compound
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
SG11202104657RA (en) 2018-11-23 2021-06-29 Bayer Ag Formulation of contrast media and process of preparation thereof
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik

Also Published As

Publication number Publication date
KR20030022387A (ko) 2003-03-15
WO2002013874A2 (de) 2002-02-21
JP2004506025A (ja) 2004-02-26
YU10603A (sh) 2006-05-25
AR034139A1 (es) 2004-02-04
BR0113188A (pt) 2003-06-24
EE200300061A (et) 2004-12-15
BG107542A (bg) 2003-09-30
ZA200301949B (en) 2004-12-14
EP1307236A2 (de) 2003-05-07
MXPA03001287A (es) 2003-10-06
RU2290206C2 (ru) 2006-12-27
NZ523932A (en) 2007-07-27
CN1469757A (zh) 2004-01-21
SK1572003A3 (en) 2003-10-07
CZ2003392A3 (cs) 2003-09-17
IL154385A0 (en) 2003-09-17
NO20030604L (no) 2003-04-11
HUP0300736A2 (hu) 2003-09-29
PL365596A1 (en) 2005-01-10
HRP20030173A2 (en) 2005-04-30
AU7754901A (en) 2002-02-25
CA2419223A1 (en) 2003-02-11
WO2002013874A8 (de) 2002-06-13
UA82642C2 (uk) 2008-05-12
NO20030604D0 (no) 2003-02-07
AU2001277549B2 (en) 2007-02-08
HUP0300736A3 (en) 2010-01-28
TWI296931B (en) 2008-05-21

Similar Documents

Publication Publication Date Title
DE10066210B4 (de) Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
DE19948651B4 (de) Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
EP1904462A2 (de) Perfluoralkylhaltige komplexe, verfahren zu deren herstellung, sowie deren verwendung
EP1307446B1 (de) Perfluoralkylhaltige komplexe mit zuckerresten, verfahren zu deren herstellung und ihre verwendung
DE102005033902B3 (de) Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
US6818203B2 (en) Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
EP1163231B1 (de) Perfluoralkylamide, ihre herstellung und ihre verwendung in der diagnostik
EP1307237B1 (de) Perfluoralkylhaltige komplexe mit polaren resten, verfahren zu deren herstellung und ihre verwendung
US6641797B2 (en) Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
DE102006049821A1 (de) Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE10040380A1 (de) Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques, Tumoren und Nekrosen
DE102005033903B4 (de) Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel

Legal Events

Date Code Title Description
Q172 Divided out of (supplement):

Ref document number: 10040380

Country of ref document: DE

Kind code of ref document: P

8110 Request for examination paragraph 44
AC Divided out of

Ref document number: 10040380

Country of ref document: DE

Kind code of ref document: P

8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

AC Divided out of

Ref document number: 10040380

Country of ref document: DE

Kind code of ref document: P

8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee